ICON Public Limited Company (ICLR)
USD 204.4
(0.56%)
USD 204.4
(0.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 755.64 Million USD | -43.95% |
| 2022 | 1.34 Billion USD | 49.75% |
| 2021 | 900.31 Million USD | 116.39% |
| 2020 | 416.06 Million USD | 4.46% |
| 2019 | 398.29 Million USD | 1.51% |
| 2018 | 392.37 Million USD | -0.67% |
| 2017 | 395.01 Million USD | 2.52% |
| 2016 | 385.3 Million USD | 0.22% |
| 2015 | 384.46 Million USD | -1.17% |
| 2014 | 389 Million USD | 7.92% |
| 2013 | 360.44 Million USD | 10.13% |
| 2012 | 327.3 Million USD | 11.12% |
| 2011 | 294.54 Million USD | 10.5% |
| 2010 | 266.56 Million USD | -2.14% |
| 2009 | 272.37 Million USD | -1.49% |
| 2008 | 276.5 Million USD | 33.58% |
| 2007 | 207 Million USD | 36.62% |
| 2006 | 151.51 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 99.97 Million USD | 27.49% |
| 2003 | 78.42 Million USD | 42.66% |
| 2002 | 54.97 Million USD | 33.14% |
| 2001 | 41.28 Million USD | 35.04% |
| 2000 | 30.57 Million USD | 52.88% |
| 1999 | 20 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 298.12 Million USD | 57.35% |
| 2024 Q2 | 194.45 Million USD | 9.65% |
| 2024 Q1 | 177.35 Million USD | -9.31% |
| 2023 Q1 | 345.13 Million USD | -6.46% |
| 2023 FY | 755.64 Million USD | -43.95% |
| 2023 Q4 | 195.56 Million USD | -40.96% |
| 2023 Q2 | 332.86 Million USD | -3.55% |
| 2023 Q3 | 331.21 Million USD | -0.49% |
| 2022 FY | 1.34 Billion USD | 49.75% |
| 2022 Q1 | 336.66 Million USD | -1.67% |
| 2022 Q2 | 333.97 Million USD | -0.8% |
| 2022 Q3 | 308.64 Million USD | -7.58% |
| 2022 Q4 | 368.98 Million USD | 19.55% |
| 2021 FY | 900.31 Million USD | 116.39% |
| 2021 Q1 | 115.94 Million USD | 10.39% |
| 2021 Q4 | 342.38 Million USD | -1.43% |
| 2021 Q3 | 347.34 Million USD | 173.16% |
| 2021 Q2 | 127.16 Million USD | 9.68% |
| 2020 Q4 | 105.02 Million USD | 5.11% |
| 2020 Q3 | 99.91 Million USD | 0.56% |
| 2020 FY | 416.06 Million USD | 4.46% |
| 2020 Q2 | 99.35 Million USD | -4.02% |
| 2020 Q1 | 103.51 Million USD | 1.6% |
| 2019 Q2 | 98.39 Million USD | 1.01% |
| 2019 Q1 | 97.4 Million USD | -0.64% |
| 2019 Q3 | 100.6 Million USD | 2.25% |
| 2019 FY | 398.29 Million USD | 1.51% |
| 2019 Q4 | 101.89 Million USD | 1.28% |
| 2018 Q2 | 97.98 Million USD | 0.17% |
| 2018 FY | 392.37 Million USD | -0.67% |
| 2018 Q3 | 97.88 Million USD | -0.1% |
| 2018 Q4 | 98.03 Million USD | 0.16% |
| 2018 Q1 | 97.81 Million USD | -0.45% |
| 2017 Q3 | 95.71 Million USD | 0.51% |
| 2017 Q2 | 95.22 Million USD | -0.64% |
| 2017 Q1 | 95.83 Million USD | -3.18% |
| 2017 FY | 395.01 Million USD | 2.52% |
| 2017 Q4 | 98.26 Million USD | 2.66% |
| 2016 Q4 | 98.98 Million USD | 3.35% |
| 2016 Q3 | 95.77 Million USD | 1.22% |
| 2016 Q1 | 95.9 Million USD | -2.75% |
| 2016 FY | 385.3 Million USD | 0.22% |
| 2016 Q2 | 94.62 Million USD | -1.34% |
| 2015 Q1 | 93.48 Million USD | -6.3% |
| 2015 Q3 | 96.8 Million USD | 1.29% |
| 2015 FY | 384.46 Million USD | -1.17% |
| 2015 Q4 | 98.61 Million USD | 1.88% |
| 2015 Q2 | 95.56 Million USD | 2.23% |
| 2014 Q1 | 90.49 Million USD | -0.96% |
| 2014 FY | 389 Million USD | 7.92% |
| 2014 Q4 | 99.76 Million USD | 1.59% |
| 2014 Q2 | 100.54 Million USD | 11.1% |
| 2014 Q3 | 98.2 Million USD | -2.33% |
| 2013 Q4 | 91.37 Million USD | -1.73% |
| 2013 Q3 | 92.98 Million USD | 4.4% |
| 2013 Q2 | 89.06 Million USD | 2.35% |
| 2013 FY | 360.44 Million USD | 10.13% |
| 2013 Q1 | 87.02 Million USD | 3.9% |
| 2012 Q1 | 78.31 Million USD | 0.77% |
| 2012 Q2 | 80.24 Million USD | 2.46% |
| 2012 Q3 | 81.29 Million USD | 1.31% |
| 2012 Q4 | 83.75 Million USD | 3.03% |
| 2012 FY | 327.3 Million USD | 11.12% |
| 2011 Q2 | 66.67 Million USD | -3.17% |
| 2011 Q4 | 77.72 Million USD | -4.4% |
| 2011 Q3 | 81.29 Million USD | 21.93% |
| 2011 FY | 294.54 Million USD | 10.5% |
| 2011 Q1 | 68.85 Million USD | -2.1% |
| 2010 Q3 | 68.01 Million USD | 1.2% |
| 2010 Q2 | 67.2 Million USD | 10.14% |
| 2010 Q1 | 61.01 Million USD | -23.55% |
| 2010 FY | 266.56 Million USD | -2.14% |
| 2010 Q4 | 70.33 Million USD | 3.41% |
| 2009 Q4 | 79.81 Million USD | 27.15% |
| 2009 Q1 | 68.74 Million USD | 0.36% |
| 2009 FY | 272.37 Million USD | -1.49% |
| 2009 Q3 | 62.77 Million USD | -4.22% |
| 2009 Q2 | 65.53 Million USD | -4.67% |
| 2008 Q1 | 66.64 Million USD | -83.81% |
| 2008 FY | 276.5 Million USD | 33.58% |
| 2008 Q4 | 68.5 Million USD | -2.74% |
| 2008 Q3 | 70.43 Million USD | -0.7% |
| 2008 Q2 | 70.93 Million USD | 6.43% |
| 2007 Q3 | 56.53 Million USD | 20.01% |
| 2007 FY | 207 Million USD | 36.62% |
| 2007 Q1 | 42.84 Million USD | 1.92% |
| 2007 Q4 | 411.65 Million USD | 628.1% |
| 2007 Q2 | 47.11 Million USD | 9.97% |
| 2006 FY | 151.51 Million USD | 0.0% |
| 2006 Q3 | 39.67 Million USD | 9.95% |
| 2006 Q4 | 42.03 Million USD | 5.94% |
| 2006 Q1 | 33.72 Million USD | 11.18% |
| 2006 Q2 | 36.08 Million USD | 7.0% |
| 2005 Q4 | 30.33 Million USD | 0.3% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | 42.08 Million USD | 46.04% |
| 2005 Q2 | 31.08 Million USD | -26.13% |
| 2005 Q3 | 30.24 Million USD | -2.72% |
| 2004 FY | 99.97 Million USD | 27.49% |
| 2004 Q2 | 25.98 Million USD | 1.51% |
| 2004 Q3 | 26.4 Million USD | 1.59% |
| 2004 Q4 | 28.81 Million USD | 9.15% |
| 2004 Q1 | 25.6 Million USD | 3.35% |
| 2003 Q1 | 19.75 Million USD | 6.66% |
| 2003 FY | 78.42 Million USD | 42.66% |
| 2003 Q4 | 24.77 Million USD | 4.91% |
| 2003 Q3 | 23.61 Million USD | -1.3% |
| 2003 Q2 | 23.92 Million USD | 21.08% |
| 2002 Q4 | 18.52 Million USD | 14.27% |
| 2002 FY | 54.97 Million USD | 33.14% |
| 2002 Q2 | 15 Million USD | 7.18% |
| 2002 Q1 | 14 Million USD | 9.47% |
| 2002 Q3 | 16.21 Million USD | 8.05% |
| 2001 Q3 | 13.17 Million USD | -9.68% |
| 2001 Q1 | 9.46 Million USD | -6.56% |
| 2001 Q4 | 12.78 Million USD | -2.94% |
| 2001 Q2 | 14.58 Million USD | 54.09% |
| 2001 FY | 41.28 Million USD | 35.04% |
| 2000 Q3 | 9.42 Million USD | 12.17% |
| 2000 Q4 | 10.13 Million USD | 7.55% |
| 2000 Q2 | 8.4 Million USD | 10.37% |
| 2000 Q1 | 7.61 Million USD | 11.93% |
| 2000 FY | 30.57 Million USD | 52.88% |
| 1999 Q4 | 6.8 Million USD | 1.49% |
| 1999 FY | 20 Million USD | 0.0% |
| 1999 Q2 | -49.3 Million USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | 6.7 Million USD | 113.59% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | -407.167% |
| Prenetics Global Limited | 60.73 Million USD | -1144.131% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -4543.824% |
| CareDx, Inc | 277.76 Million USD | -172.041% |
| Exact Sciences Corporation | 2.06 Billion USD | 63.328% |
| Exagen Inc. | 52.29 Million USD | -1345.017% |
| Inotiv, Inc. | 246.9 Million USD | -206.049% |
| Guardant Health, Inc. | 901.62 Million USD | 16.191% |
| Biodesix, Inc. | 77.41 Million USD | -876.043% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -19161.444% |
| Precipio, Inc. | 13.63 Million USD | -5440.717% |
| iSpecimen Inc. | 16.27 Million USD | -4542.322% |
| Natera, Inc. | 938.98 Million USD | 19.526% |
| Aspira Women's Health Inc. | 24.11 Million USD | -3033.628% |
| Standard BioTools Inc. | 113.48 Million USD | -565.829% |
| 23andMe Holding Co. | 420.73 Million USD | -79.602% |
| Castle Biosciences, Inc. | 242.78 Million USD | -211.242% |
| Personalis, Inc. | 128.14 Million USD | -489.683% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -583.685% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -4483.343% |
| OpGen, Inc. | 30.65 Million USD | -2364.753% |
| T2 Biosystems, Inc. | 41.49 Million USD | -1721.09% |
| Myriad Genetics, Inc. | 600.1 Million USD | -25.92% |
| NeoGenomics, Inc. | 341.25 Million USD | -121.433% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -4543.824% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 30.855% |
| RadNet, Inc. | 268.87 Million USD | -181.035% |
| MDxHealth SA | 71.25 Million USD | -960.462% |
| Psychemedics Corporation | 11.33 Million USD | -6567.046% |
| Illumina, Inc. | 3.81 Billion USD | 80.182% |
| Check-Cap Ltd. | 19.28 Million USD | -3817.888% |
| Twist Bioscience Corporation | 354.18 Million USD | -113.35% |
| DarioHealth Corp. | 62.17 Million USD | -1115.388% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -339.568% |
| Sera Prognostics, Inc. | 39.91 Million USD | -1793.036% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -7082.416% |
| OPKO Health, Inc. | 574.68 Million USD | -31.488% |
| Medpace Holdings, Inc. | 187.68 Million USD | -302.623% |
| Neogen Corporation | 405.23 Million USD | -86.469% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -6353.633% |
| Prenetics Global Limited | 60.73 Million USD | -1144.131% |
| Mainz Biomed B.V. | 27.15 Million USD | -2682.771% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -8521.295% |
| Trinity Biotech plc | 46.49 Million USD | -1525.213% |
| Neuronetics, Inc. | 82.25 Million USD | -818.614% |
| Sotera Health Company | 300.46 Million USD | -151.49% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -8521.295% |